Cystic Fibrosis: ETI Tri-therapy Shows Incomplete Respiratory Improvement in Some Adults

A national French study involving over 2,320 adult cystic fibrosis patients indicates that despite significant benefits from the elexacaftor-tezacaftor-ivacaftor (ETI) tri-therapy, nearly a third exp…

Generic image of medical laboratory equipment with a petri dish.
AI

Generic image of medical laboratory equipment with a petri dish.

A national French study conducted by AP-HP reveals that nearly one-third of adult cystic fibrosis patients treated with the innovative elexacaftor-tezacaftor-ivacaftor (ETI) tri-therapy still show diminished respiratory function, despite the treatment's significant benefits.

The study, involving over 2,320 adult patients followed in 31 French centers, confirms the major therapeutic advances brought by CFTR protein modulators, such as the ETI tri-therapy. This treatment partially restores the function of the CFTR protein, responsible for cystic fibrosis, and significantly improves respiratory function.
However, researchers observed that nearly a third of patients continue to suffer from a persistent decline in their respiratory function, even under treatment. Cystic fibrosis, a rare genetic disease, leads to the production of thick mucus that primarily affects the lungs and digestive system, promoting infections and lung degradation.
These findings, published on November 20, 2026, underscore the need to strengthen medical monitoring for adult cystic fibrosis patients. They also highlight the importance of developing new complementary therapeutic strategies aimed at further improving CFTR protein function or targeting bacterial infection and lung inflammation to better prevent respiratory decline.
Based on information from the official source: AP-HP (20/11/2026)